Anacapa Technologies Revenue and Competitors

San Dimas, CA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Anacapa Technologies's estimated annual revenue is currently $5.3M per year.(i)
  • Anacapa Technologies's estimated revenue per employee is $155,000

Employee Data

  • Anacapa Technologies has 34 Employees.(i)
  • Anacapa Technologies grew their employee count by -3% last year.

Anacapa Technologies's People

NameTitleEmail/Phone
1
Regional Sales RepresentativeReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Anacapa Technologies?

Anacapa Technologies, Inc. is a market leader and innovator in the formulation of broad spectrum antimicrobial wound care products. Anasept® Antimicrobial Skin & Wound Cleanser and Gel is a powerful board-spectrum, topical antimicrobial that is long-acting, crystal clear and highly-viscous, available in a tube as a hydrogel or as a liquid in spray and pour bottles. What will Anasept® treat? • Anasept® Antimicrobial Skin & Wound Gel is a long-acting thick hydrogel indicated for the management of partial to full thickness wounds, pressure ulcers, diabetic foot ulcers, surgical incisions, first and second degree burns, donor, and graft sites. • Anasept® Antimicrobial Skin & Wound Cleanser (liquid & spray) is used for general antiseptic site preparation for central line, graft-fistula cannulation and wound cleansing and debridement. • There is no known resistance to Anasept®. Anasept® quickly kills infection causing bacteria (including MRSA, VRE, C. difficile), C. difficile spores, pathogenic fungi, Hepatitis and HIV. • Anasept® is unmatched in eliminating the foulest orders • Anasept® is also known to assist with the effective debridement of necrotic slough and bio-debris due to its unique molecular action.

keywords:N/A

N/A

Total Funding

34

Number of Employees

$5.3M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7M356%N/A
#2
$10.3M408%N/A
#3
$10M4354%N/A
#4
$10.2M44-4%N/A
#5
$8.5M474%N/A